PRISMAP is the European medical radionuclide programme on the production of high-purity radionuclides by mass separation. We federate a European consortium of the key intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical and healthcare research institutes in the active translation of the emerging radionuclides into medical diagnosis and treatment.
PRISMAP offers a single-entry point to researchers who are seeking innovative radionuclides of high purity grade for medical applications. Our aim is to enable and accelerate early phase research on radiopharmaceuticals, targeted drugs for cancer, theranostics and personalised medicine. Through our web access platform, interested researchers may discover all available radionuclides and services offered by PRISMAP, sorted based on the available radionuclides along the periodic system of the elements, by geographical location of the facilities, and along the stages for innovative radiopharmaceutical development up to first in-human studies.
We offer trans-national access to the following goods, facilities, and services: